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Abstract
Background: IARS2 encodes a mitochondrial isoleucyl-tRNA synthetase, a highly conserved nuclear-encoded
enzyme required for the charging of tRNAs with their cognate amino acid for translation. Recently, pathogenic
IARS2 variants have been identified in a number of patients presenting broad clinical phenotypes with autosomal
recessive inheritance. These phenotypes range from Leigh and West syndrome to a new syndrome abbreviated
CAGSSS that is characterised by cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing
loss, and skeletal dysplasia, as well as cataract with no additional anomalies.
Methods: Genomic DNA from Iranian probands from two families with consanguineous parental background and
overlapping CAGSSS features were subjected to exome sequencing and bioinformatics analysis.
Results: Exome sequencing and data analysis revealed a novel homozygous missense variant (c.2625C > T, p.
Pro909Ser, NM_018060.3) within a 14.3 Mb run of homozygosity in proband 1 and a novel homozygous missense
variant (c.2282A > G, p.His761Arg) residing in an ~ 8 Mb region of homozygosity in a proband of the second family.
Patient-derived fibroblasts from proband 1 showed normal respiratory chain enzyme activity, as well as unchanged
oxidative phosphorylation protein subunits and IARS2 levels. Homology modelling of the known and novel amino
acid residue substitutions in IARS2 provided insight into the possible consequence of these variants on function
and structure of the protein.
Conclusions: This study further expands the phenotypic spectrum of IARS2 pathogenic variants to include two
patients (patients 2 and 3) with cataract and skeletal dysplasia and no other features of CAGSSS to the possible
presentation of the defects in IARS2. Additionally, this study suggests that adult patients with CAGSSS may manifest
central adrenal insufficiency and type II esophageal achalasia and proposes that a variable sensorineural hearing
loss onset, proportionate short stature, polyneuropathy, and mild dysmorphic features are possible, as seen in
patient 1. Our findings support that even though biallelic IARS2 pathogenic variants can result in a distinctive,
clinically recognisable phenotype in humans, it can also show a wide range of clinical presentation from severe
pediatric neurological disorders of Leigh and West syndrome to both non-syndromic cataract and cataract
accompanied by skeletal dysplasia.
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Background
Aminoacyl-tRNA synthetases (ARSs) are evolutionarily
conserved enzymes that catalyze amino acid attachment
to their cognate tRNA. This catalytic process, termed
tRNA charging, is a prerequisite for the translation of
genetic sequences into polypeptide chains [1]. Two dis-
tinct translation pathways take place in the cytoplasm
and in the mitochondria each requiring a separate set of
ARSs for the translation of nuclear and mitochondrial
genes respectively; in total, there are 37 members of the
ARS gene family. Two groups of 17 ARSs are each asso-
ciated with cytoplasmic or mitochondrial translation,
while three so-called bifunctional proteins act in both
cellular locations [2, 3]. Based on their cellular
localization and function, nomenclature for ARSs fol-
lows a systematic scheme that entails the recognised
amino acid, followed by ARS for both cytoplasmic and
bifunctional enzymes (i.e. IARS for cytoplasmic
isoleucyl-tRNA synthetase), and a “2” is added to distin-
guish mitochondrial ARSs (i.e. IARS2 for mitochondrial
isoleucyl-tRNA synthetase) [2, 3]. Although expression
of ARSs is ubiquitous and protein synthesis is expected to
be systemically impaired, a number of highly diverse clin-
ical phenotypes can emerge from mutations in genes en-
coding ARSs that affect a wide range of tissues with
particularly high metabolic demands [3].
IARS2 is a nuclear-encoded mitochondrial isoleucyl-tRNA
synthetase that is imported from the cytosol into the mito-
chondria where it catalyzes the attachment of an isoleucine
residue to a cognate mt-tRNAIle [4]. Genetic mutations in
IARS2 (OMIM: 612801) on chromosome 1q41 were first de-
scribed in an extended French-Canadian family with a syn-
drome abbreviated CAGSSS that is characterised by
cataracts, growth hormone deficiency, sensory neuropathy,
sensorineural hearing loss, and skeletal dysplasia [5]. A de-
tailed follow-up on two previously published first-cousin
probands from a genealogically related French-Canadian
family dating back to the nineteenth century was also ex-
plored [5, 6]. The three probands in this extended family
were homozygous for a pathogenic missense variant
(c.2726C >T, p.Pro909Leu) in exon 21 of the 23 exon IARS2
gene. The proline residue exchange affected a predicted
anticodon binding domain. An additional Danish proband
presenting CAGSSS features was identified with a homo-
zygous pathogenic variant (c.2620C > A, p.Gly874Arg)
also affecting exon 21 [7]. One further proband with com-
pound heterozygous mutations (c.1821G > A, p.Trp607*;
c.2122G >A, p.Glu708Lys) was diagnosed with Leigh syn-
drome and died at the age of 18 months [5]. Furthermore,
compound heterozygous variants in IARS2 (case 6:
c.607G > C; p.(Gly203Arg) and c.2575 T > C; p.(Phe859-
Leu)); family 10: c.2446C > T; p.(Arg816*) and c.2575 T >
C; p.(Phe859Leu)) have been found in two probands from
China with sporadic pediatric cataract which characterised
by far the mildest clinical presentation of IARS2-related
disorders [8]. Moreover, recently identified novel com-
pound missense variants in IARS2 (c.680 T > C;
p.(Phe227Ser) and c.2450G >A; p.(Arg817His)) have been
reported in one family with two Japanese siblings showing
milder symptoms of CAGSSS and West syndrome con-
comitant with Leigh syndrome [9]. Thus, these reports as-
sert that mutations in IARS2 are responsible for a
phenotypic spectrum of rare autosomal recessive disorders
that require further clinical characterisation.
In this study, we analysed whole exome sequencing
data in two unrelated consanguineous Iranian patients
presenting with clinical features overlapping with
CAGSSS. Exome analysis revealed different novel homo-
zygous variants in IARS2 in both families. Patient 1 dis-
closed a homozygous c.2725C > T, p.Pro909Ser variant
which interestingly affects the same p.Pro909 amino acid
residue that was described in the French-Canadian fam-
ily. In the exome analysis of patient 2, whose clinical fea-
tures were limited to only cataract and skeletal dysplasia,
we identified a novel homozygous c.2282A > G,
p.His761Arg variant in a region of homozygosity span-
ning 8 Mb. Additionally, we present a detailed and com-
parative clinical assessment of patients with a
phenotypic spectrum of IARS2-related disorders and il-
lustrate the predicted impact of the identified patient
mutations on the protein structure. Moreover, cultured
fibroblasts of patient 1 were analysed for mitochondrial
enzymatic activity and protein extracts were immuno-
blotted to assess key mitochondrial oxidative phosphor-
ylation (OXPHOS) proteins and steady-state IARS2
levels. Our patients, who have mild forms of CAGSSS,
highlight the wide spectrum of clinical severity associ-
ated with IARS2 mutations. Furthermore, as proband 1
displays CAGSSS symptoms concomitant with growth
hormone deficiency, central adrenal insufficiency, as well
as type II esophageal achalasia, we propose that the
phenotypic spectrum of CAGSSS-related disorders
resulting from IARS2 variants could include this constel-
lation of features.
Methods
Informed written consent was obtained from the fam-
ilies prior to their inclusion in the study. This study
was performed under the tenets of the Declaration of
Helsinki and approved by the Ethics Commission of the
University of Würzburg (46/15), as well as the Ethical
Commission of Sabzevar University of Medical Sciences
(IR.medsab.rec.1395.120). Blood samples were collected
from all participants. Genomic DNA was extracted
from whole blood using a standard salting out method.
DNA samples were quantified using Qubit 2.0 (Life
Technologies, Carlsbad, CA, USA).
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Next generation sequencing and bioinformatics analysis
Whole exome capture was performed using an Agi-
lent SureSelect Human All Exon V6 Kit according to
manufacturer’s recommendations and paired-end se-
quenced on HiSeq 4000 and HiSeq 2500 sequencers.
Exome data were processed for analysis using a
GATK-based pipeline [10] that used Burrows-Wheeler
alignment [11] to the GRCh37/hg19 human genome as-
sembly. Variant filtering was performed using the follow-
ing parameters: exonic variants with flanking splice site
regions were filtered for quality, and frequency-based
data filtering employed MAF ≤ 0.001 as defined by the
1000 Genomes Project [12] and EVS (ESP6500) (http://
evs.gs.washington.edu/EVS/) [accessed May, 2017] popu-
lation data. Artifact-prone gene families (HLAs, MAGEs,
MUCs, NBPFs, ORs and PRAMEs) were further ex-
cluded and the analysis focused on missense, stopgain/
stoploss, startgain/startloss, splicing and indel variants.
Variant prioritization was aided by the tools FATHMM
[13], MutationAssessor [14], MutationTaster [15],
PolyPhen-2 [16], and SIFT [17]. Additionally, the EVS,
gnomAD [18], GME Variome Project [19], Iranome [20],
Ensembl Variant Table [21], ClinVar [22], and HGMD
(2017.1) [23] were used for variant analysis. Variants
occurring with MAF > 0.01 in the Iranome were also
excluded. Splice sites were analysed using the Alamut
Visual 2.7 (Interactive Biosoftware, Rouen, France)
splicing module. Putative pathogenic variant
prioritization followed the following criteria: either
three out of five pathogenicity prediction tools score
the variant as deleterious or disease causing, or iden-
tified variants or adjacent variants affect an amino
acid already associated with a genetic disorder entered
in databases such as ClinVar or HGMD. In both
cases, population frequency database variant entries
are in accordance with standards for frequencies of
rare disease causing alleles [24]. The remaining vari-
ants were filtered for known disease causing genes
first and we prioritized homozygous variants due to
the autosomal recessive inheritance pattern of disease
and family consanguinity.
Variant validation and segregation testing
The IARS2 (GenBank Reference: NM_018060.3)
c.2282A > G and c.2725C > T homozygous variants
were subjected to bidirectional Sanger sequencing val-
idation with an ABI 3130xl 16-capillary sequencer
(Life Technologies, Carlsbad, CA, USA) for segrega-
tion analysis in each respective family. Primer se-
quences that were designed using Primer3 [25] are
available upon request. DNA sequence analysis was
performed using Gensearch software (Phenosystems
SA, Wallonia, Belgium).
Western blotting
Human fibroblasts were treated as described previously
[26]. Proteins of interest were bound by overnight incuba-
tion at 4 °C with antibodies against IARS2 (Sigma Prestige
cat# HPA024212), COXI (Abcam cat# ab14705, RRID:
AB_2084810), SDHA (Abcam cat# ab14715, RRID:
AB_301433), Total OXPHOS Human Antibody Cocktail
containing antibodies against ATP5A, UQCRC2, SDHB,
COXII and NDUFB8 (Abcam cat# ab110411), followed by
HRP-conjugated secondary antibodies (Dako Cytomation)
and visualised using ECL-prime (GE Healthcare) and
BioRad ChemiDoc MP with Image Lab software.
Assessment of mitochondrial respiratory chain enzyme
activities
The activities of individual respiratory chain complexes
and the mitochondrial matrix marker enzyme, citrate
synthase, were assessed as previously described [27].
Homology modelling
Homology modelling of the human mitochondrial iso-
leucine tRNA ligase (IARS2, NCBI: NP_060530.3) was
based on the structure of the isoleucine tRNA ligase
from S. aureus (PDB 1FFY) as the template. IARS2 was
built in the amino acid range 58–1012 (sharing 36%
amino acid identity with the bacterial homologue)
employing the following procedure. All side chain atoms
in the template were removed, amino acids were
renamed and renumbered to the corresponding human
IARS2 residues according to the pairwise sequence align-
ment (Additional file 1), and the modified PDB file was
parsed to SIDEpro [28] for side chain reconstruction.
The tRNAIle molecule cocrystallized with isoleucine
tRNA ligase from S. aureus (PDB 1FFY) and Ile-AMS
(an isoleucyl-adenylate analogue) cocrystallized with the
isoleucine tRNA ligase from T. thermophilus (PDB
1JZQ) were added to the human IARS2 model in same
binding poses to this ligase as in the crystal structure
complexes. Finally, the side chains of the protein were
energy minimised applying the Dreiding force field.
Results
Case presentations
Patient 1 (family 1)
The male proband (Fig. 1a, individual V:3), was born
after an uncomplicated pregnancy at 34 weeks gesta-
tional age with a 2700 g (25th centile) birth weight and
50 cm (50th centile) length to healthy parents who were
first-cousins. At the time of his birth, his father and
mother were 29 and 25 years old, respectively. The pro-
band presented with congenital cataracts that required
surgery, as well as corneal opacity, bilateral nystagmus,
and slight strabismus of the right eye (Table 1, Add-
itional file 2). He was diagnosed with myopia with a
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visual acuity of 20/40. At birth, he disclosed spastic fea-
tures and type II achalasia that was confirmed and
treated using endoscopy. Throughout early childhood,
he experienced delayed motor development; however,
this resolved spontaneously later on. No evidence of
cognitive performance limitations has been observed.
The proband is presently 20.6 years old. He shows a
proportionate short stature (height of 152 cm (− 3.4 SD),
a muscle wasted appearance (weight 30 kg, body mass
index of 13 kg/m2 (− 7.5 SD)) and mild craniofacial dys-
morphic features consisting of thick eyebrows, midface
retrusion, underdeveloped ala nasi, short philtrum, thin
upper lip, vertical crease of the chin, prognatism, and
long neck.
A growth hormone deficiency (GHD) was diagnosed,
resulting from the combination of severe short stature,
delayed bone aged, and very low IGF-1 (− 2 SD) [29]. No
growth hormone treatment was available. After repeated
measurements, a remarkable decreased serum cortisol
level (2.6 μg/dl) and a normal amount of plasmatic
adrenocorticotropic hormone (ACTH) in the morning
(8 AM) were noted, revealing central adrenal insuffi-
ciency. Thyroid-stimulating (TSH), total triiodothyron-
ine (T3), total thyroxine (T4), follicle-stimulating,
luteinising, and parathyroid hormones were within refer-
ence ranges. An isolated aldosterone measurement
showed very high levels at 440 pmol/L (Additional file
2).
Sensorineural hearing loss was diagnosed at 13 years
of age (Table 1). Pure-tone audiometry was performed
according to best-practice recommendations [30] and re-
vealed a bilateral, stable, mid-to-high frequency moder-
ate hearing loss at ages 16 and 20 years of age (Fig. 1b).
Masked bone conduction revealed an air-bone gap at
the age of 16 that was later absent. Tympanograms were
normal. The patient does not use hearing aids.
Radiological examinations at age 18 years were per-
formed and revealed late manifestations of an underlying
spondylo-epi-metaphyseal dysplasia which has been pre-
viously described for CAGSSS syndrome. Skeletal
A B
D C
Fig. 1 Pedigree of patient 1, pure-tone audiograms, radiological examinations, and sequence electropherogram. a The proband’s parents are first-
degree cousins. There is no family history of CAGSSS. Genotype results for the c.2725C > T variant are represented under the tested individuals. b
Pure-tone audiograms from proband 1 at 16 (red) and 20 (blue) years of age reveal stable, sensorineural hearing loss. Right air conduction (circle),
unmasked bone conduction (bracket), and masked bone conduction (<) and left air conduction (x) and unmasked bone conduction (>) are
shown from left to right, respectively. c Radiological images depicting epiphyseal dysplasia of the distal radius and fingers with tapering (left) and
right hip with shortened femoral neck due to metaphyseal dysplasia (right). d Electropherograms of the homozygous proband (upper panel) and
representative heterozygous electrophenogram from a parent (lower panel) showing the nucleotide and amino acid exchange. The variant
position is marked with a red arrow
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abnormalities in patient 1 included mild scoliosis, bi-
lateral pes planus (with arthrodesis of the right ankle
joints performed), wrists showing epiphyseal dyplasia
of the distal radius, fingers with tapering and a right
hip with a shortened femoral neck due to metaphy-
seal dyplasia with signs of secondary arthrosis of the
hip joint (Fig. 1c).
Electrodiagnostic testing of the left limb at 16 years of
age showed abnormal results that were consistent with
chronic sensorimotor distal axonal polyneuropathy. It
revealed extremely low amplitude or absent sensory
nerve action potentials and weakening of the upper and
lower limbs with a near-normal motor nerve conduction
velocity.
Cranial CT and brain MRI were normal (data not
shown).
Patients 2 and 3 (family 2)
Family 2, like family 1, is also of Iranian descent with
parents being first cousins (Fig. 2a). Two out of four sib-
lings, both females, were diagnosed with cataract at
birth. These females are now 35 years old (patient 2)
and 27 years old (patient 3). They were both born after
an uneventful pregnancy, had a normal birth weight. At
birth, no fundus could be identified in patient 2 during
ophthalmological investigations and she showed slight
strabismus of the right eye. She received a corneal graft
later on, which was rejected when she was 30 years-old.
She further presented mild craniofacial dysmorphic fea-
tures consisting of a flat forehead, protruding upper jaw,
mildly thickened eyebrows and deep set eyes. Radio-
logical examination showed a mild deformity of the fem-
oral head, small capital femoral epiphyses and
hypoplastic, poorly formed acetabular roofs (Fig. 2b). It
may be likely that a waddling gait may later develop.
Knees show metaphyseal widening and irregularities
while hands show brachydactyly (short fingers) and
proximal metacarpal rounding. Hearing tests and growth
hormone levels were found to be normal.
Her younger sister, patient 3 presented with a similar
phenotype of invisible fundus due to the cataract, light
strabismus of the right eye and she also received a cor-
neal graft that was rejected when she was 20 years old.
Like her older sister, she had normal hearing tests and
normal growth hormone levels. She presented with short
stature and a similar mild craniofacial dysmorphology as
observed in her sister consisting of flattened forehead,
protruding upper jaw and mildly thickened eyebrows, as
well as deep set eyes (Table 1, Additional file 2).
Molecular genetic analysis
Patient 1 (family 1)
Whole exome sequencing of patient 1 disclosed 26,052
exonic variants. After applying standard quality filtering
(22,603 remaining variants), minor allele frequency (MAF)
filtering (≤ 0.001) (1563 remaining variants), known
artifact prone gene family filtering (1015 remaining vari-
ants) and non-synonymous filters, there were 706 variants
remaining of which 648 were heterozygous and 58 homo-
zygous. No putative pathogenic heterozygous variants of
interest were found. Of the 58 homozygous variants, a sin-
gle novel homozygous missense c.2725C > T, p.Pro909Ser
variant in the gene IARS2 (GenBank: NM_018060.3,
NP_060530.3) was prioritised as a putative pathogenic
variant on the basis that this change affects the same resi-
due that was clinically and functionally proven to be
causative in a proband with CAGSSS [5] and the patient
had clinical features that fit a CAGSSS diagnosis. Further,
this variant was found to reside in a large run of homozy-
gosity spanning nearly 14.3 Mb on chr1q41q42.2 that in-
cluded 102 additional genes (homozygous interval
coordinates: rs10779261 to rs2493145; chr1:216,595,30
6-230,891,248). No variant in any of the other genes
within this interval remained after filtering. In silico ana-
lysis of synonymous variants in genes within this interval
likewise did not reveal any variants predicted to affect spli-
cing. The homozygous IARS2 variant was confirmed in
patient 1 using Sanger sequencing and both parents were
found to be heterozygous (Fig. 1d). A variety of in silico
pathogenicity prediction tools were used to assess this
missense variant (Table 2): MutationTaster predicted the
variant to be disease causing, whereas FATHMM, Muta-
tionAssessor, PolyPhen-2 and SIFT ranked the conse-
quence of the exchange as tolerated or benign. This
apparently novel variant was not deposited in any of the
publicly available population frequency databases such as
the Exome Variant Server (EVS), gnomAD, Greater Mid-
dle Eastern Variome (GME), Iranome, and Ensembl Vari-
ant Table (Table 2).
Patients 2 and 3 (Family 2)
WES was performed on the DNA from patient 2 in the
family. On the assumption that the disease follows an
autosomal recessive inheritance in the family due to
the presence of consanguinity, we prioritised homozy-
gous variants. We further preformed filtering using a
minor allele frequency cut off of 0.1% in population da-
tabases such as EVS, ExAC, gnomAD, Iranome, and
Ensembl given the rare phenotype and excluded
non-coding variants except within 10 bp of splice sites
as well as synonymous variants. The filtered data nar-
rowed down the variants to a homozygous single nucleo-
tide exchange in exon 18 of IARS2 currently known
monogenic disease-causing genes (c.2282A > G;
p.His761Arg) (Fig. 2c) located within an 8 Mb region of
homozygosity on chr1q. The variant has not been ob-
served in any public variant database and it is predicted
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to affect a highly conserved functionally important
isoleucyl-tRNA synthetase domain of the protein. The
variant was validated by Sanger sequencing, confirm-
ing both patient 2 and 3 having the variant in a
homozygous state, whereas parents and the only avail-
able healthy sibling were heterozygous. No other
pathogenic/highly pathogenic variant in currently
known monogenic disease-causing genes was identi-
fied from the WES data (Mendeliome filtering).
Both variants identified in Families 1 and 2 have been
submitted to the Leiden Open Variation Database v.3.0
(LOVD3) with individual IDs 00163754 and 00181201,
respectively (https://databases.lovd.nl/shared/genes/
IARS2).
Protein conservation analysis and homology modelling of
IARS2 amino acid substitutions
Amino acid conservation analysis and homology model-
ling of the three previously published and novel IARS2
amino acid substitutions (Glu708Lys, His761Arg,
Gly874Glu, Pro909Leu, and Pro909Ser) was performed.
For comparative analysis, the Glu708Lys exchange that
A
B
C
Fig. 2 Pedigree of patients 2 and 3, radiological examinations, and sequence electropherogram. a The proband’s parents are first-degree cousins.
There is no family history of CAGSSS. Genotype results for the c.2282A > G variant are represented under the tested individuals. b Radiological
images showing that the first metacarpale bone of the right hand (left) projects short and stunted and the plane x-ray the hyperextension of the
metacarpophalangeal and the carpophalangeal joints of the thumb is noticeable. The carpal bones show some mild dysplasia and flattening and
tapering of the distal phalanges is visible. Some mild dysplasia of the acetabulum is noticeable (right). On both sides a distinct cross over sign is
visible. The femoral heads showing some irregular shape with flattened appearance known as pistol grip deformity. The femoral neck seems
shortened in comparison to the opposite side. c Electropherograms of the homozygous proband (upper panel) and representative heterozygous
electropherogram (lower panel) showing the nucleotide and amino acid exchange. The variant position is marked with a red arrow
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was reported in compound heterozygosity with a trun-
cating mutation (Trp607*) in the Leigh syndrome pro-
band was included. The Glu708, His761, Gly874, and
Pro909 positions are well-conserved to Danio rerio
(Fig. 3a). IARS2 comprises a tRNA synthetase domain
that contains HIGH and KMSKS motifs, an
anticodon-binding domain, and an FPG IleRS zinc finger
domain (Fig. 3b). The Glu708 residue appears directly
involved in the interaction with the tRNA sugar back-
bone and also in determining IARS2 conformation (Fig.
3c). The Gly874 and Pro909 residues appear to reside in
the same anticodon-binding domain.
The His761, Gly874 and Pro909 residues appear to
reside in the same anticodon-binding domain. The
Gly874Glu substitution affects the N-terminus of an
α-helix that interacts with tRNA. Near the latter site of
mutation and on another α-helix is where the His761Arg
replacement occurs. The Pro909 is part of a loop ex-
posed to the solvent that is not near the active site. It
also appears to not be directly involved in tRNA binding
(Fig. 3c).
Functional analysis of cultured fibroblasts
We next investigated patient fibroblasts of patient 1 to
assess whether we could detect a functional consequence
of the p.Pro909Ser variant. We detected no obvious de-
fects in any mitochondrial respiratory chain enzyme ac-
tivities when related to the activity of the mitochondrial
matrix enzyme, citrate synthase (Fig. 4a). In agreement
with this, the steady-state levels of OXPHOS subunits
were unchanged between patient and control fibroblast
samples (Fig. 4b). Moreover, steady-state IARS2 protein
levels were also unchanged in the patient samples (Fig.
4b).
Review of clinical presentation of patients with
pathogenic variants in IARS2
A detailed clinical summary of the seven patients with
pathogenic variants in IARS2 can be found in Additional
file 2. A shorter summary presenting the key clinical fea-
tures observed in the 10 cases known to date can be
found in Table 1. The youngest published patient at
8 years of age was from Denmark with a homozygous
c.2620G > A, p.Gly874Glu variant [7], whereas the ex-
tended French-Canadian family had a segregating
c.2726C > T, p.Pro909Leu homozygous variant that in-
volved two previously described patients, patient 1 and
patient 2 [6] who were related to an affected individual,
case 1 [5]. Also, case 4, with Scandinavian-Caucasian
ethnicity had compound heterozygous variants
[(c.1821G > A, p.(Trp607*); c.2122G > A, p.(Glu708Lys)]
[5]. Of note, case II-1 and II-2 in the Japanese study had
segregating compound heterozygous variants [(c.680 T >
C; p.[(Phe227Ser)] and c.2450G > A; p. [(Arg817His)] [8].
In the current study, patients in family 1 (patient 1) and
family 2 (patient 2 and patient 3) have the c.2725C > T,
p.Pro909Ser and c.2282A > G, p.His761Arg homozygous
variants, respectively.
Ocular findings
Ocular findings are amongst the most common features
associated with IARS2 loss of function variants in seven
out of ten probands affected by bilateral nystagmus and/
or cataracts at birth or within the first three years of life
(Table 1). Corneal opacifications have likewise been ob-
served in six out of ten patients. Ocular abnormalities
generally appear progressive. Particularly excellent
follow-up of the ocular findings of patient 7 in Table 1
(case 1 described by Schwartzentruber and colleagues),
included the description of a number of failed corneal
grafts and severe eye dryness [31]. Furthermore, this pa-
tient had a history of congenital neurotropic keratitis,
orbital myopathy and ptosis of the right eye (Table S1).
Optical coherence tomography also revealed foveal hy-
poplasia. Unfortunately, the other cases have not been
studied in this detailed manner. However, orbital myop-
athy and slight strabismus of the right eye are also over-
lapping phenotypes reported in patient 1.
Endocrinology
A main feature of CAGSSS is short stature and growth
hormone deficiency that was noted in two of ten pa-
tients (Table 1). Not all patients may have been investi-
gated in depth and the Danish proband reported normal
growth hormone levels at 4 years of age. However, the
authors remarked this may be due to her young age [7].
In Table 1, patient 7 had low growth hormone levels at
15 years of age that worsened to a severe deficiency at
22 years of age [5]. Growth hormone replacement ther-
apy was performed in patient 7 and patient 8 with posi-
tive outcomes. The presumed central cortisol deficiency
of patient 7 would suggest an adrenal insufficiency is
present, although this was not directly described [5]. Pa-
tient 1 showed a combination of growth hormone defi-
ciency and central adrenal insufficiency, which could be
associated with a hypothalamic-pituitary axis dysfunc-
tion. Hypoglycemia, which can be linked to central ad-
renal insufficiency, was noted in patient 7 and patient 9
[32].
Sensory neuropathy
Half of all patients presented with peripheral neuropathy
with a broad age of onset starting as early as 8 months
of age (Table 1). A loss of small and medium-sized mye-
linated fibres, particularly in the hands, was reported in
two of these patients. Decreased sensation to pinprick,
temperature, and touch in all four extremities was
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Fig. 3 (See legend on next page.)
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reported in patient 7 [5]. Pain insensitivity was noted in
early childhood in another patient [7].
Sensorineural hearing loss
Four out of ten patients reported to date were found to
exhibit sensorineural hearing loss with a broad age of
onset ranging from 18 months to 13 years of age (Table
1). Hearing aids were used in only two of these cases
(Additional file 2). Previous publications did not show
pure-tone audiograms or in-depth audiological testing
results. Patient 8 was described with a 60 to 70 dB
low-frequency and 50 dB high-frequency hearing loss
at the age of 21 months and brainstem auditory
evoked potentials corresponding to a 60 dB bilateral
sensorineural hearing loss [6]. The most recent audio-
gram from patient 1 shows gently sloping
mid-to-high-frequency moderate sensorineural hearing
loss to 45 to 50 dB (Fig. 1c).
Musculoskeletal alterations
Nine out of ten patients presented with short stature,
of which, three exhibited disproportionate short stat-
ure and likewise, three cases were diagnosed with
spondylo-epi-metaphyseal dysplasia (Table 1). All pa-
tients with radiological examinations presented irregu-
lar metaphyses and delayed epiphyseal ossification
was found in three cases. Seven of ten cases pre-
sented with spine abnormalities, of which four pre-
sented with scoliosis. Hip dislocation was observed in
four cases, joint hypermobility in three cases, and two
probands had genu valgum. A muscular wasting ap-
pearance was clearly evident in patient 1.
Discussion
CAGSSS is a rare but highly distinctive syndrome with a
unique constellation of features, arising from biallelic
mutations in IARS2. The patients we described here
show a considerable phenotypic overlap to previously
described patients. However, not all cases fulfill all fea-
tures of the CAGSSS acronym. We found significant
variability regarding onset of symptoms and some indi-
viduals show additional symptoms not included in the
acronym, suggesting a wider phenotypic spectrum. With
only ten molecularly confirmed cases reported to date,
genotype-phenotype correlations are difficult to make
with certainty, but it seems possible that there is a
(See figure on previous page.)
Fig. 3 IARS2 scheme, sequence alignment and homology model. a Sequence alignment among vertebrates (H. sapiens, NP_060530.3; M.
musculus, NM_198653.2; C. anna, XM_008492093.1; G. gallus, NM_001006397.1; C. mydas, XM_007064764.1; X. tropicalis, NM_001127043.1; L.
chalumnae, XM_005998405.2; D. rerio, XM_021467083.1) around the sites of the missense mutations discussed in the text (Glu708Lys, His761Arg,
Gly874Arg, Pro909Leu, and Pro909Ser). Residues that are invariant in this group of organisms are shown in gray. b Schematic view of IARS2
protein indicating mutations (those reported in this study and the published ones) and colored by phenotype. c Homology model of IARS2. The
protein ribbon has the same colors that are shown in the functional regions of the protein in panel B. The residues affected by the missense
mutations are highlighted by surfaces with the same color scheme as in panel B. The bound cognate tRNA (tRNAIle) is shown as ribbon and sticks
in light orange, and the Ile-AMP analogue as yellow sticks
A B
Fig. 4 Biochemical and western blot analyses of patient fibroblasts. a Activity of mitochondrial respiratory complexes in control (red) and patient
(blue) fibroblast samples. Mean enzyme activities normalised to citrate synthase (CS) of control fibroblasts (n = 8) are set to 100% and error bars
represent standard deviation. b Western blots of protein lysate from patient fibroblasts (P) and two age-matched controls (C1 and C2)
immunodecorated with antibodies against IARS2, NDUFB8 (CI), UQCRC2 (CIII), COXI (CIV), COXII (CIV) and ATP5A (CV). SDHA and SDHB (CII) were
used as loading controls
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predicted milder impact of the p.Pro909Ser variant on
IARS2 protein function compared to the other identified
alleles (Table 1).
Type II achalasia and adrenal insufficiency were ob-
served in two individuals, patient 1 and patient 7 and
interestingly both have a homozygous variant affecting
the proline on position 909, p.Pro909Ser in patient 1
and p.Pro909Leu in patient 7 [5]. Due to the low cortisol
values in patient 7, we also speculate an adrenal insuffi-
ciency that would require further studies. It would be
particularly interesting for additional patients with
IARS2 pathogenic variants to be monitored for adrenal
insufficiency. The replicated finding of esophageal acha-
lasia suggests an expansion of the CAGSSS phenotypic
spectrum. Achalasia, a primary motor disorder of the
esophagus, is typically diagnosed in adulthood [33].
Therefore, it is unsurprising that it was not mentioned
as a clinical feature in the Danish proband [7]. This may
also be an unlikely coincidence that achalasia was also
described in a French-Canadian proband [5]. One could
speculate that IARS2 could be one of many genetic fac-
tors for this phenotype; however, further reports are re-
quired to understand this observation.
In silico analysis suggests the c.2725C > T, p.Pro909Ser
variant is likely benign with only one out of five in silico
pathogenicity prediction tools ranking this variant as dis-
ease causing. Also, two out of five of these tools pre-
dicted the novel c.2282A > G, p.His761Arg variant in the
current study as disease causing (Table 2). While these
tools can be a helpful first insight to the pathogenicity of
a variant, no single program provides an error-free pre-
diction result and caution should be used with conclud-
ing pathogenicity based exclusively on in silico tools
[34]. Based on previous studies, we assessed whether the
p.Pro909Ser variant led to any demonstrable effects on
OXPHOS function and steady-state IARS2 levels in pa-
tient fibroblasts although none were detected. This was
somewhat surprising given the earlier report of the pa-
tient with the c.2726C > T, p.Pro909Leu variant docu-
mented decreased levels of IARS2 protein in patient
cells [5]. Despite this, it is well documented that muta-
tion of human mitochondrial ARSs are associated with
marked clinical heterogeneity and tissue-specificity, and
that cultured skin fibroblasts rarely replicate the func-
tional mitochondrial deficit observed in post-mitotic and
clinically-relevant tissues [35–37].
Evolutionary conservation of structurally and function-
ally important regions is typically a criterion for inferring
pathogenicity. Conserved regions have been subjected to
negative selection and disease causing variants tend to
occur disproportionately in highly conserved amino
acids [38]. The homology model of human IARS2 allows
the observation that the Glu708Lys variant, a variant as-
sociated with Leigh syndrome, affects a glutamic acid
directly involved in the binding of mt-tRNAIle (at the
level of nucleotide G69 as inferred from the crystal
structure of the complex of tRNAIle with a bacterial iso-
leucine tRNA ligase, PDB code 1FFY), and is also very
close to the catalytically important KMSKS motif and
also nearby the binding site of Ile-AMP (Fig. 3b). The lo-
cation of Glu708 inside the protein can be reliably
assessed from the sequence alignment with the bacterial
template (Additional file 1). Thus, it could be expected
that the conserved Glu708 might have roles in the cor-
rect function of IARS2 and that the Glu708Lys change,
which implies a reversal of the electric charge at this
site, would somehow influence the enzyme activity.
However, the possible clinical importance of the
Glu708Lys variant expected from modelling does not ap-
pear to be supported by population frequency data,
which show a combined eight homozygous (five South
Asian individuals, two non-Finnish Europeans, and one
Central Asian (GME) individual) and 374 heterozygous
carriers from the five population frequency databases
used (Table 2) and yielded a combined calculated MAF
of 0.00131. In combination with the null Trp607* trun-
cating mutation in the Leigh syndrome patient, [5], we
speculate that the Glu708Lys variant alone has moderate
severity but may still be functional and provide a viable
amount of enzymatic activity but not enough to over-
come a null allele. Supported by population frequency
data, a homozygous null Trp607* variant is likely to be
lethal. We assert that a homozygous Glu708Lys orienta-
tion in IARS2 may provide enough enzymatic activity to
be viable, and in light of the population frequency data,
phenotypically normal. Thus, it remains to be seen
whether an association with Leigh syndrome is correct.
Phenotypic presentation is also likely absent in the con-
text of variants that mildly disrupt synthetase activity
over a certain threshold, since sufficient synthetase activ-
ity can be maintained by even low functional activity
[39]. Further studies are necessary to understand the
role of this variant.
The His761Arg and Gly874Arg amino acid exchanges
occur very close to each other (Fig. 3c). The Gly874Arg
exchange affects a conserved glycine in the N-terminus
of a helix involved in the binding of mt-tRNAIle (Fig. 3c)
and might influence this interaction through conform-
ational changes. As a matter of fact, the Gly874Arg
change introduces a large and cationic residue very close
to Lys872, thus producing both hindrance and repulsive
electric forces promoting conformational changes in the
helix. The interactions between the latter helix and the
helix bearing His761 might be altered by the replace-
ment of this conserved histidine with an arginine. The
Pro909Leu and Pro909Ser variants affect a conserved
proline in a solvent exposed loop. Both replacements
modify the flexibility of the loop as proline residues
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provide unique conformational restraints among
amino acids. In the case of the Pro909Leu variant,
since Pro909 is surrounded by the hydrophobic
Ile907, Leu911, and Ile954 residues (Fig. 3c), we fore-
see that the additional hydrophobic residue intro-
duced by mutation would favour clustering of these
hydrophobic residues to minimise their exposure to
water. Therefore, the Pro909Leu change is expected
to cause more prominent conformational changes
compared to the Pro909Ser variant wherein the
hydrophilic nature of the loop is preserved by the
serine residue. This is consistent with the more severe
phenotype associated with the Pro909Leu variant
compared to the Pro909Ser variant.
Presently, most of the CAGSSS pathogenic missense
variants that have been identified reside in exon 21
(Gly874Arg, Pro909Leu, Pro909Ser) of IARS2. It remains
unknown whether homozygous variants in this exon
tend to be associated with CAGSSS and variants of un-
known significance in other affected exons are respon-
sible for Leigh syndrome, a syndrome that is attributed
to the death of a patient at 18 months of age that was
proposed to be due to compound heterozygous IARS2
variants (c.1821G > A, p.Trp607* in exon 14 and
c.2122G > A, p.Glu708Lys in exon 17) [5]. Japanese sib-
lings who were diagnosed with CAGSSS, Leigh, and
West syndrome showed compound heterozygous vari-
ants in IARS2 that affected exons 4 (c.680 T > C,
p.Phe227Ser) and 20 (c.2450G > A, p.Arg817His). Pa-
tients 2 and 3 presented with ophthalmological and skel-
etal deficits and had a homozygous variant in exon 18. It
can be reasoned that loss-of-function variants result in a
more severe phenotype, since tRNA-charging activity
would be abolished. This effect is likely independent of
the affected exon.
Although no other endocrine disorders have been
connected to other patients with mutations in IARS2,
mitochondrial disease itself represents a high risk for a
variety of endocrine diseases. GHD has been related to
multiple patients with mitochondrial encephalomyopa-
thy lactic acidosis and stroke-like episodes (MELAS),
mtDNA deletions disorders, and nuclear encoded de-
fects [40]. The hypothalamic-pituitary axis dysfunction
has been proposed as the underlying pathophysiological
mechanism, including chronic ischemia and energy de-
ficiency of the diencephalon, associated with the mito-
chondrial genetic abnormality of the hypothalamus.
This may correlate with our patient, since he shows a
co-existing central adrenal insufficiency. Adrenal insuf-
ficiency has also been characterised in several patients
with other forms of mitochondrial dysfunction, mostly
with Kearns-Sayre syndrome, Person syndrome,
MELAS, and POLG-related disease [41]. The most ac-
cepted pathophysiological mechanism is associated with
the high energy demands of endocrine glands; there-
fore, the impaired mitochondrial ATP production and/
or oxidative stress may greatly reduce the ability to se-
crete hormone or maintain normal feedback [40].
Whilst this manuscript was in peer review, two add-
itional publications described IARS2 variants in patients.
One of the reports described a Japanese family with two
siblings who were diagnosed with Leigh syndrome that
was concomitant with some of the features of CAGSSS,
as well as West syndrome (Table 1 patients 4 and 5) [9].
Both siblings had novel, compound heterozygous IARS2
[(c.680 T > C; p.[(Phe227Ser)] and c.2450G > A; p.
[(Arg817His)] variants in exons 4 and 20, respectively,
and exhibited delayed motor development, as well as in-
fantile spasms and abnormal brain MRI diagnostic im-
aging leading to a diagnosis of Leigh syndrome. One of
the two siblings had cataracts and the other sibling had
a neonatal hearing screening result requiring follow-up.
Both female children were in their first decade of life at
the time of publication.
The second publication which characterised by far the
mildest clinical presentation characterized to date de-
scribed two probands from China with sporadic
pediatric cataract [8]. Both probands were identified with
compound heterozygous variants in IARS2 (case 6:
c.607G > C; p.(Gly203Arg) in exon 4 and c.2575 T > C;
p.(Phe859Leu) in exon 21; family 10: c.2446C > T;
p.(Arg816*) in exon 20 and c.2575 T > C; p.(Phe859Leu)
in exon 21). Both probands shared the Phe859Leu ex-
change, which affects the anticodon-binding domain and
can be reasoned to exhibit only mild/moderate effects.
One of the reasons for this hypothesis is that the amino
acid exchange conserves hydrophobicity. Another being
that the Gly203Arg that is located in the
aminoacyl-tRNA synthetase domain and the Arg816*
null allele can reasonably be predicted as causing more
severe effects on the protein. If the Phe859Leu exchange
were to cause a severe protein change, we would expect
a severe or even lethal phenotype in the presence of the
null allele. Thus, the allelic protein product with the
Phe859Leu exchange should still maintain functionality.
Conclusions
In conclusion, we describe two additional independent
families with a total of three affected individuals display-
ing clinical features overlapping with CAGSSS and novel
IARS2 variants, expanding the clinical and mutational
spectrum. Patient 1 also presented with type II esopha-
geal achalasia, as well as growth hormone deficiency and
central adrenal insufficiency, which could result from
dysfunction of the hypothalamic-pituitary axis. The un-
usual combination of findings suggest that other endo-
crine disorders in patients with an IARS2-associated
mitochondriopathy could likewise be possible and
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should be excluded. We propose that these additional
phenotypes expand the syndromic constellation of symp-
toms in adults. Early recognition of IARS2-related patho-
physiology has potentially important implications in
clinical management, seeing that undetected adrenal in-
sufficiency could lead to a life threatening crisis.
Additional files
Additional file 1: Sequence alignment used for homology modelling of
IARS2 protein. (DOCX 16 kb)
Additional file 2: Comprehensive clinical summary of patients with
pathogenic variants in IARS2. (DOCX 24 kb)
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